Ablative Solutions receives innovation award

325

Ablative Solutions was the recipient of a “Top Cardiovascular Innovation Award” from Cardiovascular Research Technologies for the Peregrine system. The Peregrine system is a percutaneous catheter designed to deliver diagnostic and therapeutic agents through vessel walls to the outer region of arteries.

The Peregrine System has been cleared by the US Food and Drug Administration (FDA) for the infusion of diagnostic and therapeutic agents into the perivascular area. Ablative Solutions is currently investigating the use of the Peregrine System in a clinical study in Europe intended to secure a CE mark. The System is being evaluated for renal denervation, providing a treatment that delivers therapy directly to the nerves that run along the perimeter of the renal artery. The interruption of these nerve pathways may have therapeutic implications for hypertension, metabolic syndrome, congestive heart failure and obesity. The System is not currently cleared or approved in the USA for renal denervation, or for the treatment of hypertension, metabolic syndrome, congestive heart failure or obesity.

“In selecting the Peregrine System as an award recipient, we recognised the originality, elegance and the demonstrated capabilities of this approach of chemical denervation, which has the potential to have a therapeutic impact in the field of hypertension and other related diseases,” shared Ron Waksman, director of the annual Cardiovascular Revascularization Therapies meeting.

Tim Fischell, co-founder and chief executive officer of Ablative Solutions, presented the Peregrine System during the Innovation in cardiology session. “It is an honour to be recognised for innovation,” noted Fischell. “Our team has worked diligently in the research and development, preclinical and clinical evaluation of this approach of chemical denervation, motivated by the belief that we can help physicians make a significant impact in the treatment of devastating diseases like hypertension and other metabolic disorders caused by overactive sympathetic nerves. We look forward to continued evaluation of this therapeutic approach.”